AbbVie announced the start of two Phase 2 clinical trial programs to evaluate ABBV-8E12, an investigational anti-tau antibody, in patients with early Alzheimer's disease and progressive supranuclear palsy (PSP). In recognition of the lack of treatment options available to patients with PSP, the U.S. Food and Drug Administration granted Fast Track Designation to ABBV-8E12. The FDA and European Medicines Agency also granted Orphan Drug Designations to ABBV-8E12 for PSP. After consultation with the FDA and EMA, AbbVie is beginning the Phase 2 clinical trial programs following completion of pre-clinical studies and a Phase 1 study in patients with PSP, which supported the further development of ABBV-8E12 in PSP and early Alzheimer's disease. Positive results from the Phase 1 study in PSP were recently released at the Clinical Trials on Alzheimer's Disease (CTAD) annual meeting in December 2016. The Phase 2 study in early Alzheimer's disease will enroll 400 patients to assess the efficacy and safety of ABBV-8E12 to delay disease progression (NCT02880956). The Phase 2 study in PSP will evaluate 180 adults and assess the efficacy and safety of ABBV-8E12 to slow disease progression (NCT02985879).